



# Addiction Therapy-2014

Chicago, USA

August 4 - 6, 2014



Lynda Sharrett-Field

# Preclinical Studies of Glucocorticoid Receptor Antagonists in the Treatment of Alcohol Dependence

Lynda Sharrett-Field<sup>1</sup>, Hilary J. Little<sup>2</sup>,  
Mark Prendergast<sup>1</sup>

<sup>1</sup>Department of Psychology, University of Kentucky,


<sup>2</sup>Division of Addictions, Institute of Psychiatry, University of London

# Current FDA Approved Treatments for Alcohol Dependence

- Antabuse
- Naltrexone
  - ▣ Vivitrol
- Acamprosate
  
- Alcohol Withdrawal
  - ▣ Benzodiazepines

# Stress and Addiction

- HPA Axis and Addiction:
  - Cortisol / Corticosterone
  - Type 1: Mineralocorticoid receptors (MR)
    - High affinity
  - Type 2: Glucocorticoid receptors (GR)
    - Low affinity



# Stress and Addiction

## □ Preclinical Studies:

- Rats will self-administer CORT to physiological levels achieved with the presentation of stress.

(Piazza et al, 1993)


- Administration of CORT increases self-administration of psychostimulants

(Goeders, 1996)

- Administration of CORT or presentation of stressor increases self-administration of alcohol


(Faulke et al, 1994)

# Potential Mechanism of CORT/DA Interaction




# Voluntary Intermittent Ethanol Consumption and CORT

BELs and plasma CORT levels following 1hr of EtOH exposure are positively correlated



Basal plasma CORT levels are associated with voluntary EtOH Consumption



## Slide 7

---

- 1 Recently found similar evidence that CORT response is + correlated with voluntary EtOH consumption.

CORT levels predict drinking durin 24 hr period

Animals that consumed high EtOh levels during first 24hrs of exposure demonstrated elevated levels of CORT


Lynda Sharrett-Field, 7/30/2014




# Forced Continuous Ethanol Consumption and Corticosterone

- Elevations in corticosterone differ across brain regions and are affected by abstinence.

3 week exposure ethanol via liquid diet



3 weeks ethanol via liquid diet  
6 days of abstinence



(Little et al., 2008)

## Slide 8

---


### SL1

Importance of withdrawal in producing elevations CORT.

Different brain regions are exposed to different levels of CORT.

Sharrett-Field, Lynda, 7/29/2014

# Ethanol withdrawal (EWD) induced neuronal damage reduced by RU486



(Mulholland et al., 2005)

- Organotypic hippocampal slice cultures
- CORT (1  $\mu$ M) exposure during EWD resulted in significant loss of cells, which is reduced by GR antagonism.

## Slide 9

---

### SL3

high levels of CORT are observed in the hippocampus

study looked at how these elevated levels of CORT are affecting the region during EWD

RU but not Spir reduced CORT+EWD effects, suggesting the effects are mediated by GR not MR

temporal lobe structures such as hippo are where many seizures begin during EWD. RU486 might be protective if given during EWD.

Sharrett-Field, Lynda, 7/29/2014

# Glucocorticoid Antagonists

- GR receptor antagonist:
  - RU486 (Mifepristone)
    - Termination of pregnancy (Progesterone receptor)
    - Cushing's Syndrome
    - Depression with psychotic tendencies
    - Combat related PTSD
  - ORG34517 and ORG22189



## Slide 10

---

**SL9**

Points:

difference btwn high and low affinity indicates which will be implicated in mediating flux in CORT levels


receptors are intracellular, discuss where they are concentrated within the brain

difference in PR activity between RU486 and ORG analogs

Sharrett-Field, Lynda, 7/29/2014


# Cognitive effects of EWD and exposure reduced by RU486

**A** Difference in time spent exploring novel and familiar objects



Single administration of RU486 (mif) prior to EWD reversed alcohol induced alterations on the object recognition task.

**B** Total exploration time



Behavior assessed 8-10 days following withdrawal from 34 weeks of chronic alcohol treatment in CJ57 mice

**Slide 11**

---

**SL5**

These are CJ57 mice, 34 weeks of exposure.

Sharrett-Field, Lynda, 7/29/2014




# Behavioral effects of EWD reduced by RU486

4 day binge exposure:

Ethanol administered via gavage 3 times daily  
Injections of RU486 or vehicle given once daily  
prior to first daily ethanol dose

- Tremor
- Splayed paws
- Rigidity
- “Wet dog shakes”



## Slide 12

---

### SL6

RU456 can protect from cognitive effects if given prior to EWD, but can also reduce the behavioral effects associated with EWD. Important bc benzos currently most often prescribed drug given during detox, which does NOT protect against cognitive loss.


Sharrett-Field, Lynda, 7/29/2014

# Preference for alcohol is reduced by RU486

Low alcohol preferring mice

2 Bottle Choice:  
8% EtOH or tap water

Once daily i.p. injection  
Saline or RU486



## Slide 13

---

### SL8

RU456 can protect from cognitive effects if given prior to EWD, but can also reduce the behavioral effects associated with EWD. Important bc benzos currently most often prescribed drug given during detox, which does NOT protect against cognitive loss.

Sharrett-Field, Lynda, 7/29/2014

# Summary

- Basal levels of CORT are predictive of voluntary ethanol consumption
- Exposure to and withdrawal from chronic ethanol administration elevates levels of CORT
- Elevations of CORT during EWD produces cell loss in the hippocampus, *in vitro*.
- Administration of RU486 during EtOH or EWD:
  - ▣ Reduce cognitive deficits
  - ▣ Reduce behavioral signs of EWD
- RU486 reduces ethanol preference

# Human Trials

- Co-Investigators- Hilary Little and Colin Drummond
- Participants
  - Alcoholics entering Alcohol Treatment Units for detoxification
    - DSM-IV for 5 or more years
    - Male aged 18-60 years
  - Randomized double blind trial
- Treatment
  - RU486 or placebo given upon drinking cessation and for following two weeks
- 12 month trial
  - Weeks 1-4:
    - Several assessments of withdrawal severity
    - Depressive symptomology
    - Sleep disturbances
    - Cognitive assessment
  - Follow-up at 3, 6, 12 months
    - Abstinence & relapse
    - Depressive symptomology

# Acknowledgements

- Mark Prendergast
  - NIAAA
    - Grant: AA013388 & AA013561
- Hilary Little
  - NIAAA
    - Grant: AA13932
  - Medical Research Council



Meet the eminent gathering once again at

# Addiction Therapy-2015

Florida, USA

August 3 - 5, 2015

Addiction Therapy – 2015 Website:

[addictiontherapy.conferenceseries.com](http://addictiontherapy.conferenceseries.com)